Article

FDA requires further study for oral voclosporin

The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

Jersey City, NJ-The FDA has issued a complete response letter regarding a new drug application (NDA) for oral voclosporin (Luveniq, Lux Biosciences) for the treatment of non-infectious uveitis, according to the company.

The FDA issues such a letter when it has reviewed a file but has questions that preclude the approval of the NDA in its current form. Lux Biosciences and its partner, Isotechnika Pharma, are evaluating the letter but indicate that the agency said that it regards the data from one of the two pivotal studies submitted in the NDA as positive. Officials at Lux Biosciences said the company plans to begin an additional pivotal trial of oral voclosporin before the end of the year.

“We continue to work with FDA to address [its] outstanding questions regarding the safety and efficacy of [oral voclosporin], and the Lux Biosciences’ Board of Directors is supportive of our starting the additional trial,” said Dean Mitchell, Lux Biosciences’ president and chief executive officer. “At the same time, the European Medicines Agency review of the marketing authorization application [MAA] for [oral voclosporin] remains on course for completion in the first quarter of 2011.”

The company announced submission of the NDA and MAA for oral voclosporin Feb. 3.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.